Progression/death
primary disease, AML
AML, TRANSFORMATION TO ACUTE MYELOID LEUKEMIA
80 (17.2%) patients died during the study, 25 (5.4%) patients terminated the study due to progression of primary disease, and seven (1.5%) patients terminated the study because of transformation to acute myeloid leukemia (AML).